Physician profile
Roy Sheinbaum
NPI 1053359513
$5,165.41
in general payments reported to CMS, 2019-2025
12 companies · $164 in 2025
The $164 reported for 2025 was more than what 77% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $626 · 2020: $38.47 · 2021: $2,668 · 2022: $557 · 2023: $970 · 2024: $142 · 2025: $164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,276.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,275.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acelrx Pharmaceuticals, INC. | $2,461.32 | 2019-2021 | |
| Edwards Lifesciences Corporation | $1,467.77 | 2019-2023 | Hemosphere |
| Abiomed | $289.08 | 2024-2025 | Impella |
| Medtronic, INC. | $254.70 | 2022-2023 | Avalus |
| Eagle Pharmaceuticals, INC. | $249.96 | 2023 | |
| Grifols USA, LLC | $208.01 | 2019 | |
| Atricure, INC. | $124.64 | 2022 | |
| Medtronic Vascular, INC. | $33.26 | 2019 | |
| Merck Sharp & Dohme LLC | $25.43 | 2022 | |
| Avanos Medical | $20.41 | 2019 | |
| Octapharma USA, INC. | $16.80 | 2025 | Fibryga |
| Chiesi USA, INC. | $14.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roy Sheinbaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.